Apellis (APLS) is down -17.3%, or -$4.72 to $22.58.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis reports preliminary FY25 U.S. net product revenues of $689M
- Apellis announces strategic priorities for 2026
- Apellis price target lowered to $48 from $55 at Stifel
- Apellis Pharmaceuticals: Buy Rating Affirmed Amidst European Regulatory Milestones and Long-term Growth Potential
- Roth Capital healthcare analyst holds an analyst/industry conference call